Showing 1 - 4 results of 4 for search 'Saru Basnet', query time: 0.02s Refine Results
  1. 1
    Oncolytic adenovirus decreases the proportion of TIM-3+ subset of tumor-infiltrating CD8+ T cells with correlation to improved survival in patients with cancer

    Oncolytic adenovirus decreases the proportion of TIM-3+ subset of tumor-infiltrating CD8+ T cells with correlation to improved survival in patients with cancer by Matti Kankainen, Timo Joensuu, Akseli Hemminki, Juuso Juhila, Siri Tähtinen, Otto Hemminki, Anna Kanerva, Kristian Taipale, Ilkka Liikanen, Minna Oksanen, Dafne C A Quixabeira, Saru Basnet

    Published 2022-02-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Boosting anti-tumor immunity with TILT-517 oncolytic adenovirus and checkpoint blockade in renal cell carcinoma

    Boosting anti-tumor immunity with TILT-517 oncolytic adenovirus and checkpoint blockade in renal cell carcinoma by Victor Arias, Tatiana V. Kudling, James H.A. Clubb, Elise Jirovec, Santeri A. Pakola, Mirte Van der Heijden, Saru Basnet, Dafne C.A. Quixabeira, Lyna Haybout, Nea Ojala, Susanna Grönberg-Vähä-Koskela, Anna Kanerva, Antti Rannikko, João M. Santos, Victor Cervera-Carrascon, Otto Hemminki, Akseli Hemminki

    Published 2025-06-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Oncolytic adenovirus encoding variant interleukin-2 combined with chemotherapy enables PD-L1 inhibition in pancreatic cancer models

    Oncolytic adenovirus encoding variant interleukin-2 combined with chemotherapy enables PD-L1 inhibition in pancreatic cancer models by Santeri A. Pakola, Nea Ojala, Tatiana V. Kudling, James H. A. Clubb, Elise Jirovec, Mirte van der Heijden, Victor Arias, Lyna Haybout, Saru Basnet, Susanna Grönberg-Vähä-Koskela, Dafne C. A. Quixabeira, Joao M. Santos, Victor Cervera-Carrascon, Otto Hemminki, Anna Kanerva, Harri Mustonen, Pauli Puolakkainen, Hanna Seppänen, Akseli Hemminki

    Published 2025-06-01
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    The oncolytic adenovirus TILT-123 with pembrolizumab in platinum resistant or refractory ovarian cancer: the phase 1a PROTA trial

    The oncolytic adenovirus TILT-123 with pembrolizumab in platinum resistant or refractory ovarian cancer: the phase 1a PROTA trial by Matthew Stephen Block, James Hugo Armstrong Clubb, Johanna Mäenpää, Santeri Pakola, Dafne Carolina Alves Quixabeira, Tatiana Kudling, Elise Jirovec, Lyna Haybout, Mirte van der Heijden, Sanae Zahraoui, Susanna Grönberg-Vähä-Koskela, Sini Raatikainen, Victor Arias, Saru Basnet, Nea Ojala, Teijo Pellinen, Annabrita Hemmes, Katja Välimäki, Annukka Pasanen, Tuomo Alanko, Daniel Adamo, Susan Ramadan, Jorma Sormunen, Juha Kononen, Julia Wanda Cohen, Michael Jon Chisamore, John Goldfinch, Suvi Sorsa, Riikka Havunen, Claudia Kistler, Aino Kalervo, Víctor Cervera-Carrascon, João Manuel dos Santos, Akseli Hemminki

    Published 2025-02-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: